seladelpardelparOCAursodeoxycholic acid
…brates/OCA (total, n = 131; 83%). At month 18, among continuous seladelpar patients, 9/15 (60%) patients with prior fibrate/OCA use achiev…
28articles mentioning drugs
75drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: UDCA ×
UDCA
This drug is selected. Its supporting articles are shown below.
Articles mentioning UDCA
28 articles · page 3 of 3ElafibranorelafibrinorUDCAprimary biliary cholangitisPBC
…Elafibranor is a dual PPAR-α/δ agonist recently licenced for treatment of P…
Seladelpar
… 10 mg monotherapy led to notable CBR rates and ALP reductions. Seladelpar monotherapy was well tolerated and had a similar safety profile…